Home>>BB-22 3-carboxyindole metabolite

BB-22 3-carboxyindole metabolite

Catalog No.GC42899

BB-22 is an analog of the potent synthetic cannabinoid, JWH 018 that is structurally similar to PB-22 and its derivative, 5-fluoro PB-22.

Products are for research use only. Not for human use. We do not sell to patients.

BB-22 3-carboxyindole metabolite Chemical Structure

Cas No.: 858515-71-6

Size Price Stock Qty
1mg
$163.00
In stock
5mg
$385.00
In stock
10mg
$599.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BB-22 is an analog of the potent synthetic cannabinoid, JWH 018 that is structurally similar to PB-22 and its derivative, 5-fluoro PB-22 . [1] [2]  Both BB-22 and PB-22 are distinctive in that an 8-hydroxyquinoline replaces the naphthalene group of JWH 018. BB-22 3-carboxyindole metabolite is expected to be a metabolite of BB-22 that would be detectable both in serum and urine. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.

Reference:
[1]. Sobolevsky, T., Prasolov, I., and Rodchenkov, G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 200(1-3), 141-147 (2010).
[2]. Moran, C.L., Le, V.H., Chimalakonda, K.C., et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal. Chem. 83(11), 4228-4236 (2011).

Reviews

Review for BB-22 3-carboxyindole metabolite

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BB-22 3-carboxyindole metabolite

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.